skip to Main Content
  • This page as PDF

FDA’s Expedited Programs: Is Every New Product Special?


Given the boom in programs intended to speed up development and regulatory review of drugs and biologics, are we simply turning every new product into a regulatory exception, or are these programs working as intended? Join us as we explore the opportunities and benefits of these programs, discuss how they are used by FDA, industry and the financial sector, and explain how to navigate among them to optimize your regulatory strategy.

During this webinar, you will:

    • Learn about the current FDA expedited programs and how they compare to each other

Understand how stakeholders view these programs and their relative benefits
Learn how to navigate among these programs to identify the optimal regulatory strategy for your product


Gillian Woollett , Principal Research Scientist, Commercialization & Regulatory Strategy

Gillian Woollett leads our FDA Practice.

Back To Top